Neurogene, Inc. (NGNE)
28.31
-2.94
(-9.41%)
USD |
NASDAQ |
Sep 25, 16:00
28.32
+0.01
(+0.04%)
After-Hours: 19:59
Neurogene Shareholders Equity (Quarterly) : 217.13M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 217.13M |
| March 31, 2026 | 237.78M |
| December 31, 2025 | 264.89M |
| September 30, 2025 | 265.54M |
| June 30, 2025 | 273.26M |
| March 31, 2025 | 291.80M |
| December 31, 2024 | 310.38M |
| September 30, 2024 | 137.41M |
| June 30, 2024 | 155.01M |
| March 31, 2024 | 170.78M |
| December 31, 2023 | 186.02M |
| September 30, 2023 | 75.24M |
| June 30, 2023 | 79.58M |
| March 31, 2023 | 81.36M |
| December 31, 2022 | -145.74M |
| September 30, 2022 | 105.65M |
| June 30, 2022 | 116.71M |
| March 31, 2022 | 130.09M |
| December 31, 2021 | 142.86M |
| September 30, 2021 | 154.87M |
| June 30, 2021 | 167.07M |
| March 31, 2021 | 178.97M |
| December 31, 2020 | 191.22M |
| September 30, 2020 | 200.34M |
| June 30, 2020 | 128.70M |
| Date | Value |
|---|---|
| March 31, 2020 | 137.12M |
| December 31, 2019 | 141.69M |
| September 30, 2019 | 66.88M |
| June 30, 2019 | 72.33M |
| March 31, 2019 | 71.54M |
| December 31, 2018 | 72.67M |
| September 30, 2018 | 76.72M |
| June 30, 2018 | 90.68M |
| March 31, 2018 | 85.82M |
| December 31, 2017 | 98.89M |
| September 30, 2017 | 114.09M |
| June 30, 2017 | 124.61M |
| March 31, 2017 | 136.94M |
| December 31, 2016 | 144.66M |
| September 30, 2016 | 155.36M |
| June 30, 2016 | 92.09M |
| March 31, 2016 | 102.38M |
| December 31, 2015 | 108.42M |
| September 30, 2015 | 114.03M |
| June 30, 2015 | 25.81M |
| March 31, 2015 | 30.08M |
| December 31, 2014 | 36.15M |
| September 30, 2014 | 43.98M |
| June 30, 2014 | 50.02M |
| March 31, 2014 | 55.10M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 1.307B |
| Alnylam Pharmaceuticals, Inc. | 1.354B |
| Anika Therapeutics, Inc. | 137.28M |
| Savara, Inc. | 143.66M |
| Vericel Corp. | 370.04M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 244.36M |
| Total Liabilities (Quarterly) | 27.23M |
| Debt to Equity Ratio | 0.0384 |
| Current Ratio | 10.63 |
| Net Debt Paydown Yield | 0.14% |